13 December, 2021 by The TZ Newswire Staff Comments Off on Seedo Corp Announces A Change In The Company’s Name To SATIVUS TECH CORP And The Appointment Of a CEO For Its Israeli Subsidiary, Saffron Tech
Seedo Corp Announces A Change In The Company’s Name To SATIVUS TECH CORP And The Appointment Of a CEO For Its Israeli Subsidiary, Saffron Tech
Tel Aviv, Israel, Dec. 13, 2021 (GLOBE NEWSWIRE) — SATIVUS TECH CORP (OTC: SEDOD), an AgTech company that is developing the protocols to grow saffron using vertical farming technology, today announces that has formally changed its name from Sedo Corp to SATIVUS TECH CORP. The Company also wishes to announce that it has executed a 1 for 10 reverse split of its common stock and symbol change. The new symbol will be SEDOD and after 20 business days, the symbol will change to SATT.
13 December, 2021 by The TZ Newswire Staff Comments Off on How Many Years of Maxing Out a 401(k) Does It Take to Become a Millionaire?
How Many Years of Maxing Out a 401(k) Does It Take to Become a Millionaire?
Your 401(k) can be an incredible tool when it comes to building a nest egg for your retirement. Indeed, if you leverage it well throughout your career, it can potentially be enough to make you a millionaire by the time you retire.
13 December, 2021 by The TZ Newswire Staff Comments Off on Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma
Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma
– Overall response rate of 56% and median overall survival of 32.8 months in patients with advanced AITL, an aggressive form of T-cell lymphoma –
13 December, 2021 by The TZ Newswire Staff Comments Off on Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin’s Lymphoma at the 63rd Annual Meeting of the American Society of Hematology
Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin’s Lymphoma at the 63rd Annual Meeting of the American Society of Hematology
SOUTH SAN FRANCISCO, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today reported updated data from two Phase 1 clinical trials (ALPHA and ALPHA2) of its lead anti-CD19 AlloCAR T therapy programs (ALLO-501 and ALLO-501A) at the 63rd American Society of Hematology (ASH) Annual Meeting.
13 December, 2021 by The TZ Newswire Staff Comments Off on Agios Presents Mitapivat Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis in Non-transfusion-dependent α- and β-Thalassemia at 63rd ASH Annual Meeting and Exposition
Agios Presents Mitapivat Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis in Non-transfusion-dependent α- and β-Thalassemia at 63rd ASH Annual Meeting and Exposition
– Global Phase 3 ENERGIZE and ENERGIZE-T Studies of Mitapivat in Transfusion-dependent and Non-transfusion-dependent α- and β-Thalassemia Initiated –
13 December, 2021 by The TZ Newswire Staff Comments Off on Year-end bonuses are back! Here’s what to do with yours
Year-end bonuses are back! Here’s what to do with yours
Nearly twice as many employers are offering year-end bonuses this year. Here’s how to stretch a one-time cash infusion.
13 December, 2021 by The TZ Newswire Staff Comments Off on Why the 3 Biggest Cryptocurrencies Bitcoin, Ethereum, and Binance Coin Plunged Today
Why the 3 Biggest Cryptocurrencies Bitcoin, Ethereum, and Binance Coin Plunged Today
Today’s price action in the wide world of cryptocurrencies has been broadly negative. Indeed, when the three largest tokens by market capitalization — Bitcoin (CRYPTO: BTC), Ethereum (CRYPTO: ETH) and Binance Coin (CRYPTO: BNB) — are all down, the market tends to follow suit.